Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available.
Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. **Amended 01/01/11**

Name of Entity:	**Antisense Therapeutics Limited** (ASX:ANP)
ABN:	41 095 060 745

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Mr Robert W Moses
Date of Last Notice:	23rd December 2013

Part 1 – Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	a) 31st October 2014 b) 6th November 2014 Subject to * c) 12th November 2014 Subject to **
No. of securities held prior to change	See table below
Class	Ordinary Shares
Number acquired	See table below

	Shares	Options
Direct	24,000	8,000
Indirect	2,100,000	700,001
Total	**2,124,000**	**708,001**

	Shares	Options
Direct	a) 300,000	-
	300,000	
	b) 304,348*	
	c) 130,435**	
	434,783	
Indirect	-	-
Total	**734,783**	-

*Subject to Shareholder approval on Resolution 3A at the Annual General Meeting of the Company to be held on Thursday, 6th November 2014
**Allotment and Issue of SPP Shares on Wednesday, 12th November 2014

+ See chapter 19 for defined terms.

Number disposed	<table><tr><th></th><th>Shares</th><th>Options</th></tr><tr><td>**Direct**</td><td>-</td><td>-</td></tr><tr><td>**Indirect**</td><td>-</td><td>-</td></tr><tr><td>**Total**</td><td>-</td><td>**-**</td></tr></table>
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	a) $0.113 per Share b) $0.115 per Share c) $0.115 per Share
No. of securities held after change	<table><tr><th></th><th>Shares</th><th>Options</th></tr><tr><td>**Direct**</td><td>24,000 a) 300,000 b,c) 434,783</td><td>8,000</td></tr><tr><td>**Indirect**</td><td>2,100,000</td><td>700,001</td></tr><tr><td>**Total**</td><td>**2,424,000**[#]</td><td>**708,001**</td></tr></table> [#]Excludes **b** and **c** acquisitions
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	a) On-Market Acquisition b) As per Resolution 3A to be approved by Shareholders at the Annual General Meeting of the Company c) Allotment and Issue of SPP Shares

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A